Healthcare Professionals

Healthcare Professionals

CANCER

Collaborate with us

Immunovative is seeking to collaborate with Medical Oncologists and Interventional Radiologists in our immunomonitoring research programs for cancer.  The aim of these collaborations is to develop a database on a variety of immune parameters in cancer patients at various stages in the disease process. The immune parameters include tumor-specific and polyclonal Th1/Th2 ratios, tumor-specific CTL quantification, naïve/memory ratios, plasma cytokine/chemokine levels, Treg quantification, co-stimulatory molecule expression and checkpoint molecule expression.  In addition, we can customize the immunomonitoring for specific questions.

Through collaborations, we plan on mapping immune responses before and after various treatments, including chemotherapy, radiation, radiofrequency ablation, cryoablation, high frequency ultrasound, etc.

What is Required

In order to collaborate, we need to have a Medical Summary of diagnosis and prior treatments, together with biopsy and blood samples from cancer patients sent to our Phoenix laboratory for processing.  We will then share the results of our assays as well as collaborate on the analysis of the data obtained from our worldwide collaborators.

Benefits of Collaboration

Collaborators will be assisting in developing a data base describing the baseline immune presentation of cancer patients with various indications and at various stages in the disease process before, during and after various treatments. Through multi-variant analysis, we hope to be able to identify immunological prognostic markers for response to therapy as well as determine the role of the immune response in various treatments. All collaborators will have an opportunity to serve as authors on any publicaitons and participate in collaborator symposia sponsored by Immunovative Therapies, Ltd.

How to Collaborate

If you are interested in collaborating with us, please send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

We will assist in regulatory and legal requirements.

HIV

We are seeking specialists in laboratory research and clinical trials in HIV for collaboration.  We have conducted proof-of-concept clinical study demonstrating immune control and functional cure of HIV, eliminating need for daily anti-viral treatment.  

We are seeking collaborators to conduct larger, controlled clinical trials and immunological monitoring of the mechanisms of the observed immune control.

If you are interested in discussing possible collaboration, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

 

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more